Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(12):1576–1580. doi: 10.1038/bjc.1996.297

Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer.

V Gebbia 1, A Testa 1, N Gebbia 1
PMCID: PMC2074540  PMID: 8664133

Abstract

Two doses of megestrol acetate (MA) have been prospectively compared in a random fashion as treatment for cancer-related anorexia-cachexia syndrome (ACS) in 122 patients with progressive soft tissue sarcoma, colorectal, lung, head and neck and renal cancer resistant to systemic chemotherapy. After 30 days of MA, 55% of patients receiving MA at 160 mg day-1 reported an increase in appetite, 27% of patients no variation and 18% complained of a decrease in appetite. Patients treated with MA at 320 mg day-1 reported an increase in appetite in 68% of cases, a stabilisation in 20% of cases and a decrease in 12%. Although an increase in appetite was more frequently observed in patients receiving MA at 320 mg day-1, however this difference was not statistically significant (P = 0.305). After 30 days of MA, 31% of patients treated with MA at 160 mg day-1 showed an increase in body weight, 25% a stabilisation and 44% a decrease. In the group of patients treated with MA at 320 mg day-1, 45% reported an increase in body weight, 16% no change and 23% weight loss. Although there was a trend favouring the higher dose of MA, overall analysis however failed to detect any statistically significant difference between the two treatment arms (P = 0.242). Twenty-seven patients pretreated with 160 mg day-1 and 23 patients treated with 320 mg day-1 received further therapy with MA at the dose of 320 and 480 mg day-1 respectively. In the group of 22 patients treated with 320 mg day-1 four (18%) reported an increase in body weight, eight (36%) an improvement in appetite, but none had an increase in performance status. Among the 20 evaluable patients treated with 480 mg day-1, two (10%) had an increase in body weight, four (20%) an improvement in appetite, but none reported an increase in performance status. No difference in median survival was detected between the two arms. Toxicity was mild and predictable. In conclusion, the data achieved in the present study confirm the clinical safety and effectiveness of oral MA in the management of ACS in patients with advanced cancer resistant to systemic chemotherapy. Moreover, data concerning the dose escalation of MA dosage in unresponsive patients suggest that a step by step increase in MA dosage could be the best way of administering MA for the management of ACS and that the increase of MA dosage over 480 mg day-1 will probably be useless in the vast majority of cases. Data on body weight suggest that after 2 weeks' therapy MA could be stopped or its dosage tailored to patients' needs since the majority of patients respond after only 15 days of MA.

Full text

PDF
1576

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck S. A., Tisdale M. J. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res. 1987 Nov 15;47(22):5919–5923. [PubMed] [Google Scholar]
  2. Brennan M. F. Total parenteral nutrition in the cancer patient. N Engl J Med. 1981 Aug 13;305(7):375–382. doi: 10.1056/NEJM198108133050705. [DOI] [PubMed] [Google Scholar]
  3. Bruera E., Macmillan K., Kuehn N., Hanson J., MacDonald R. N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990 Sep 15;66(6):1279–1282. doi: 10.1002/1097-0142(19900915)66:6<1279::aid-cncr2820660630>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  4. Creagan E. T., Ingle J. N., Schutt A. J., Schaid D. J. A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol. 1989 Apr;12(2):152–155. doi: 10.1097/00000421-198904000-00013. [DOI] [PubMed] [Google Scholar]
  5. DeWys W. D. Anorexia as a general effect of cancer. Cancer. 1979 May;43(5 Suppl):2013–2019. doi: 10.1002/1097-0142(197905)43:5+<2013::aid-cncr2820430709>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  6. Feliu J., González-Barón M., Berrocal A., Artal A., Ordóez A., Garrido P., Zamora P., García de Paredes M. L., Montero J. M. Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. Am J Clin Oncol. 1992 Oct;15(5):436–440. doi: 10.1097/00000421-199210000-00008. [DOI] [PubMed] [Google Scholar]
  7. Hamburger A. W., Parnes H., Gordon G. B., Shantz L. M., O'Donnell K. A., Aisner J. Megestrol acetate-induced differentiation of 3T3-L1 adipocytes in vitro. Semin Oncol. 1988 Apr;15(2 Suppl 1):76–78. [PubMed] [Google Scholar]
  8. Heckmayr M., Gatzemeier U. Treatment of cancer weight loss in patients with advanced lung cancer. Oncology. 1992;49 (Suppl 2):32–34. doi: 10.1159/000227125. [DOI] [PubMed] [Google Scholar]
  9. Knox L. S., Crosby L. O., Feurer I. D., Buzby G. P., Miller C. L., Mullen J. L. Energy expenditure in malnourished cancer patients. Ann Surg. 1983 Feb;197(2):152–162. doi: 10.1097/00000658-198302000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Loprinzi C. L., Ellison N. M., Schaid D. J., Krook J. E., Athmann L. M., Dose A. M., Mailliard J. A., Johnson P. S., Ebbert L. P., Geeraerts L. H. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990 Jul 4;82(13):1127–1132. doi: 10.1093/jnci/82.13.1127. [DOI] [PubMed] [Google Scholar]
  11. Loprinzi C. L., Jensen M. D., Jiang N. S., Schaid D. J. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc. 1992 Dec;67(12):1160–1162. doi: 10.1016/s0025-6196(12)61145-8. [DOI] [PubMed] [Google Scholar]
  12. Loprinzi C. L., Schaid D. J., Dose A. M., Burnham N. L., Jensen M. D. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993 Jan;11(1):152–154. doi: 10.1200/JCO.1993.11.1.152. [DOI] [PubMed] [Google Scholar]
  13. Miller A. A., Becher R., Schmidt C. G. Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer. J Cancer Res Clin Oncol. 1988;114(2):186–190. doi: 10.1007/BF00417835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nixon D. W., Heymsfield S. B., Cohen A. E., Kutner M. H., Ansley J., Lawson D. H., Rudman D. Protein-calorie undernutrition in hospitalized cancer patients. Am J Med. 1980 May;68(5):683–690. doi: 10.1016/0002-9343(80)90254-5. [DOI] [PubMed] [Google Scholar]
  15. Parnes H. L., Aisner J. Protein calorie malnutrition and cancer therapy. Drug Saf. 1992 Nov-Dec;7(6):404–416. doi: 10.2165/00002018-199207060-00003. [DOI] [PubMed] [Google Scholar]
  16. Schmoll E. Risks and benefits of various therapies for cancer anorexia. Oncology. 1992;49 (Suppl 2):43–45. doi: 10.1159/000227127. [DOI] [PubMed] [Google Scholar]
  17. Sedlacek S. M. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol. 1988 Apr;15(2 Suppl 1):3–13. [PubMed] [Google Scholar]
  18. Splinter T. A. Cachexia and cancer: a clinician's view. Ann Oncol. 1992 Aug;3 (Suppl 3):25–27. doi: 10.1093/annonc/3.suppl_3.s25. [DOI] [PubMed] [Google Scholar]
  19. Tchekmedyian N. S., Hickman M., Siau J., Greco F. A., Keller J., Browder H., Aisner J. Megestrol acetate in cancer anorexia and weight loss. Cancer. 1992 Mar 1;69(5):1268–1274. doi: 10.1002/cncr.2820690532. [DOI] [PubMed] [Google Scholar]
  20. Tchekmedyian N. S., Tait N., Aisner J. High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Semin Oncol. 1986 Dec;13(4 Suppl 4):20–25. [PubMed] [Google Scholar]
  21. Ternell M., Moldawer L. L., Lönnroth C., Gelin J., Lundholm K. G. Plasma protein synthesis in experimental cancer compared to paraneoplastic conditions, including monokine administration. Cancer Res. 1987 Nov 15;47(22):5825–5830. [PubMed] [Google Scholar]
  22. Tisdale M. J. Cancer cachexia. Anticancer Drugs. 1993 Apr;4(2):115–125. doi: 10.1097/00001813-199304000-00001. [DOI] [PubMed] [Google Scholar]
  23. Willemse P. H., van der Ploeg E., Sleijfer D. T., Tjabbes T., van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer. 1990 Mar;26(3):337–343. doi: 10.1016/0277-5379(90)90231-h. [DOI] [PubMed] [Google Scholar]
  24. Young V. R. Energy metabolism and requirements in the cancer patient. Cancer Res. 1977 Jul;37(7 Pt 2):2336–2347. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES